Company profile for Mediar Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Mediar is a preclinical stage biotechnology company developing therapeutics to halt, or even reverse, fibrosis. The platform and pipeline are based on an emerging class of novel targets – fibrotic mediators – that play key roles in modulating myofibroblast biology and the development of fibrosis in chronically damaged organs. Mediar’s foundational technology is based on pioneering research from Massachusetts General Ho...
Mediar is a preclinical stage biotechnology company developing therapeutics to halt, or even reverse, fibrosis. The platform and pipeline are based on an emerging class of novel targets – fibrotic mediators – that play key roles in modulating myofibroblast biology and the development of fibrosis in chronically damaged organs. Mediar’s foundational technology is based on pioneering research from Massachusetts General Hospital and Brigham and Women's Hospital. The company was founded by Partners Innovation Fund in 2018 and is located at Lab Central, Cambridge’s premier biotechnology incubator.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
700 Main Street, North Cambridge, MA 02139
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/mediar-therapeutics-doses-first-patient-in-phase-2-wisper-trial-of-mtx-463-for-idiopathic-pulmonary-fibrosis-302473778.html

PR NEWSWIRE
05 Jun 2025

https://www.prnewswire.com/news-releases/mediar-therapeutics-enters-into-global-licensing-agreement-with-lilly-to-advance-first-in-class-wisp1-antibody-for-the-treatment-of-idiopathic-pulmonary-fibrosis-ipf-302347905.html

PR NEWSWIRE
10 Jan 2025

https://www.prnewswire.com/news-releases/mediar-therapeutics-initiates-second-clinical-program-in-portfolio-of-novel-first-in-class-antibodies-designed-to-halt-fibrosis-302215886.html

PR NEWSWIRE
07 Aug 2024

https://www.pharmabiz.com/NewsDetails.aspx?aid=168956&sid=2

PHARMABIZ
07 May 2024

https://www.prnewswire.com/news-releases/mediar-therapeutics-announces-clinical-candidates-for-lead-fibrosis-programs-strategic-collaborations-and-key-leadership-addition-301966378.html

PR NEWSWIRE
25 Oct 2023
Mediar gets a spark from Pfizer’s Ignite program
Mediar gets a spark from Pfizer’s Ignite program

25 Oct 2023

// Max Bayer FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/mediar-gets-spark-pfizers-ignite-program-lead-programs-progress

Max Bayer FIERCE BIOTECH
25 Oct 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty